Annotation Detail

Information
Associated Genes
HRAS
Associated Variants
HRAS p.Gly13Asp (p.G13D) ( ENST00000311189.8, ENST00000397594.7, ENST00000397596.6, ENST00000417302.7, ENST00000451590.5 )
HRAS p.Gly13Asp (p.G13D) ( ENST00000311189.8, ENST00000397594.7, ENST00000397596.6, ENST00000417302.7, ENST00000451590.5 )
Associated Disease
colorectal cancer
Source Database
CIViC Evidence
Description
Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/699
Gene URL
https://civic.genome.wustl.edu/links/genes/2747
Variant URL
https://civic.genome.wustl.edu/links/variants/274
Rating
3
Evidence Type
Predictive
Disease
Colorectal Cancer
Evidence Direction
Supports
Drug
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Evidence Level
C
Clinical Significance
Resistance
Pubmed
26561417
Drugs
Drug NameSensitivitySupported
Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorResitance or Non-Reponsetrue